Daryl Crenshaw, MD
Nephrology · Thomasville, GANPI 1528123965
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,258 of the $29,857 with a category attached, or 81.2%. 12 manufacturers reported payments, led by Vertex at 51.3% of the total. 2025 is the largest year on record at $27,119, more than ten times the $25 reported in 2019. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $678.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$15K
- AstraZeneca$9K
- Calliditas Therapeutics US Inc.$2K
- Travere Therapeutics, Inc.$2K
- Vantive US Healthcare LLC$1K
- Johnson & Johnson$375
- plus $297 from 6 others
What the payments were for
- Consulting fees$24,25881%
- Speaking & faculty fees$3751%
- Travel & lodging$4,04614%
- Food & beverage$1,1164%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 13 | $15,307 |
| AstraZeneca | 8 | $9,187 |
| Calliditas Therapeutics US Inc. | 2 | $1,936 |
| Travere Therapeutics, Inc. | 4 | $1,677 |
| Vantive US Healthcare LLC | 6 | $1,079 |
| Johnson & Johnson | 1 | $375 |
| Aurinia Pharma U.S., Inc. | 4 | $164 |
| Akebia Therapeutics Inc | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$1,936
- Renal - Chronic$916
- INVOKANA$375
- Renal - PD$120
- FARXIGA$114
- LUPKYNIS$114
How this compares
$29,857 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 174 | $170,361 |
| VelphoroSucroferric Oxyhydroxide | 55 | $123,596 |
| Thiola EcTiopronin | 13 | $65,732 |
| MounjaroTirzepatide | 31 | $50,217 |
| JardianceEmpagliflozin | 24 | $42,744 |
| Sevelamer Carbonate | 195 | $40,078 |
| LinzessLinaclotide | 49 | $37,755 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $26,540 |
| AuryxiaFerric Citrate | 25 | $25,982 |
| OzempicSemaglutide | 19 | $20,530 |
| EliquisApixaban | 26 | $16,974 |
| ProsolParenteral Amino Acid 20% No.1 | 66 | $13,099 |
| JanuviaSitagliptin Phosphate | 11 | $8,554 |
| Calcium Acetate | 103 | $8,132 |
| MyrbetriqMirabegron | 11 | $6,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $9,187 | $196,901198 claims |
| Fresenius USA Marketing, Inc.Velphoro | $20 | $123,59655 claims |
| Akebia Therapeutics IncAuryxia | $44 | $25,98225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Thomasville
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
- William PaxtonLawrenceville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.